FTI
BPMC

Fiduciary Trust International’s Blueprint Medicines BPMC Stock Holding History

Fiduciary Trust International’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-5
Closed – – 167
2018
Q4 		$0 Buy
+5
New +$304 ﹤0.01% 656

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fiduciary Trust International's BPMC Position: Q1 2019 in Review

Fiduciary Trust International sold out of Blueprint Medicines (BPMC) in Q1 2019, closing a stake of 5 shares.

Fiduciary Trust International first reported a position in BPMC in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 203 funds tracked by Wall St. Rank hold BPMC as of Q1 2019.

  • Fiduciary Trust International reported no remaining Blueprint Medicines position as of Q1 2019 after selling out during the quarter.
  • Fiduciary Trust International sold 5 Blueprint Medicines shares in Q1 2019.
  • Fiduciary Trust International first reported a position in Blueprint Medicines in Q4 2018 and held it in 1 quarter.
  • Fiduciary Trust International's Blueprint Medicines position peaked at $0 in Q4 2018.
  • 203 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2019.

Based on Fiduciary Trust International's 13F filing for Q1 2019, filed 7 May 2019.